Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday, November 15th.

Aethlon Medical Stock Up 5.8 %

Aethlon Medical stock opened at $0.37 on Wednesday. The firm has a market cap of $5.11 million, a price-to-earnings ratio of -0.13 and a beta of 1.79. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $2.35. The business’s 50-day moving average price is $0.39 and its 200 day moving average price is $0.42.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.